Summary
The AI statements address patents/exclusivities and expiration timelines, which are not claims covered by the provided FDA-approved prescribing information excerpts. No on-label prescribing content is evaluated or supported by the label text, so alignment cannot be established.
Category Scores
Accurate Statements
Unsupported Statements
Xarelto (rivaroxaban) has multiple patents and related exclusivities.
No corresponding information about patents, exclusivities, or patent counts is provided in the supplied FDA prescribing information excerpts.
The expiration date for Xarelto depends on which specific patent is being asked about.
The supplied FDA prescribing information excerpts do not address patent expiration dates.
Patent terms differ by jurisdiction (e.g., U.S. vs. EU).
The supplied FDA prescribing information excerpts do not address patent terms by jurisdiction.
Xarelto protection can include multiple patents covering different aspects (formulations, dosing regimens, or manufacturing).
The supplied FDA prescribing information excerpts do not mention patent coverage scope (formulations, dosing regimens, or manufacturing).
Xarelto protection can include different expiry timelines across jurisdictions.
The supplied FDA prescribing information excerpts do not provide any expiry timelines related to patent protection.
Regulatory exclusivities may extend market protection beyond the last listed patent in some cases.
The supplied FDA prescribing information excerpts do not discuss regulatory exclusivities or their relationship to patent timelines/market protection.
Patents are tied to filing/priority dates with adjustments in some countries.
The supplied FDA prescribing information excerpts do not discuss patent filing/priority dates or jurisdictional adjustments.
The exact 'up' date is determined patent-by-patent rather than by the drug’s launch date.
The supplied FDA prescribing information excerpts do not discuss any 'up' dates or how they relate to patents vs. launch date.
The practical answer for Xarelto is tied to the specific patent document(s) relevant to the country you care about (U.S., EU, etc.).
The supplied FDA prescribing information excerpts do not address patent-document-driven determinations by country.
Contradictions
Important Omissions
Any FDA-label-based information relevant to the asked topic (e.g., boxed warnings, indications, contraindications, dosing, warnings/precautions) is not provided in the AI statements.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The evaluated AI response does not contain dosing or safety instructions. However, it provides unsupported patent/exclusivity claims that are unrelated to prescribing information and could mislead stakeholders if treated as label-based guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Statements concern patents/exclusivities and expiration timelines, which are not supported or addressed in the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Restrict claims to what is present in the FDA label excerpts (e.g., indications, boxed warnings, warnings/precautions, dosing/switching/discontinuation guidance) and avoid unsourced patent/protection/expiration assertions.